PHASE 3: POOLED SAFETY DATA: PSUMMIT I AND PSUMMIT II AT WEEK 16
(PLACEBO-CONTROLLED PERIOD)1
*Squamous cell carcinoma in situ in an area of cleared psoriasis.1
SAFETY DATA THROUGH WEEK 1081,3*
RATE OF SELECTED TREATMENT-EMERGENT AEs THROUGH WEEK 108 (PSUMMIT I OPEN-LABEL EXTENSION)*‖
References: 1. Data on file. Janssen Biotech, Inc. 2. STELARA® [Prescribing Information]. Horsham, PA: Janssen Pharmaceuticals, Inc; 2019. 3. Kavanaugh A, Puig L, Gottlieb AB, et al; on behalf of the PSUMMIT 1 Study Group. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015;67(12):1739-1749.